IGC Pharma, Inc. (FRA:IGS1)

Market Cap	23.78M
Revenue (ttm)	942.64K
Net Income (ttm)	-5.49M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	427
Open	0.2860
Previous Close	0.2780
Day's Range	0.2860 - 0.2860
52-Week Range	0.2320 - 0.5300
Beta	n/a
RSI	51.05
Earnings Date	Feb 13, 2026

About IGC Pharma

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capi...

• Industry: Pharmaceutical Preparations
• Founded: 2005
• Employees: 70
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IGS1

Financial Performance

In 2024, IGC Pharma's revenue was $1.27 million, a decrease of -5.50% compared to the previous year's $1.35 million. Losses were -$7.12 million, -45.22% less than in 2023.

Financial numbers in USD